Magazine: Anticipation rises for RSV rollout as positive data emerges

The last year was a momentous one for RSV research with more than one vaccine and a new treatment for infants being approved to target RSV disease. In this month’s cover story, we track how these vaccines and treatments will now get to those who need them the most by looking at the initial rollout in Spain, and what lessons that may have for the rest of the world. 

This month’s issue also features a high-profile exclusive interview with the director of Biomedical Advanced Research and Development Authority (BARDA)’s medical countermeasures programs outlining the agency’s focus areas for the future. 

Don’t miss coverage on the pricing implications of the world’s most expensive therapy, the latest fad involving molecular glues, and much more.

All this and the latest news and analysis on the pharmaceutical and biotech industry.

Read the latest issue of Pharma Technology Focus for all this and insights, and analysis from the pharmaceutical industry

You can also subscribe here to receive email notifications when a new issue is available.

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

View profiles in store

Company Profile – free sample

Your download email will arrive shortly

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Submit and download

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.